Despite the growing need for effective treatments, mental health drug discovery has faced persistent challenges: a limited number of validated targets, a lack of predictive preclinical models, and high clinical trial failure rates.
We are driving collaborative innovation to overcome the scientific and translational barriers holding back drug discovery.
The challenges facing psychiatric research require the insights and involvement of individuals across all aspects of the research landscape, providing clarity to overcome the hurdles to psychiatric drug development, leading to better patient outcomes.
By working with a variety of partners, including those in government, industry, academia and patient organisations, we are enabling smarter, faster, and more patient-centric R&D.
We believe that shared insight is the key to unlocking rapid and meaningful breakthroughs in the psychiatric medicine space.
As a life sciences service, we strategically align scientific expertise, industry, charities, and patients to address global challenges for specific diseases.
We collaboratively develop national programmes, focused on delivering impact where support is needed to improve patients’ lives.
“Mental health is a challenge that affects all of us, and it will only be solved through collaboration across the board. We are proud to help bridge the gap between discovery and delivery by bringing people together around bold, patient-focused solutions.”
Sara Imarisio, Strategy Leader
The Psychiatry Consortium is a strategic collaboration of leading medical research charities and pharmaceutical companies focusing on the challenge of identifying and validating novel drug targets to address the unmet therapeutic needs of people living with mental health conditions.
The Consortium combines the depth of the researcher’s scientific understanding with the breadth of drug discovery knowledge of our network of industry partner organisations, allowing us to turn scientific ideas into drug discovery projects.
As the managing partner, we identify the researchers who are discovering those novel targets and build a framework of expertise and resources around them to support them through the early stages of the drug discovery pipeline.
Visit websiteLaunched in 2022, the Dementia Goals Programme, formed from the Dame Barbara Windsor Dementia Goals, aims to speed up the development of new treatments for dementia and neurodegenerative conditions.
The Dementia Goals Programme is a globally unique, not-for-profit, industry-led public-private partnership that collaborates across government, industry, academia, the NHS, and charities.
MDC was the set-up delivery partner for the Dementia Goals Programme. We provided expert knowledge and collaboration to build the programme’s key foundations.
Want to collaborate or learn more about our work in mental health and psychiatry drug discovery?
We welcome researchers, clinicians, and industry partners to join us in tackling one of the most pressing global health challenges.
Fill out the form, and we will be in touch to discuss how we could possibly work together.
